

Seeing more, in less time

AI-Assisted Retinal Therapy Planning



Manuel Opitz
Co-Founder & CEO

Our partners

abbvie




NOVARTIS



HEIDELBERG
ENGINEERING

TOPCON



Disclaimer deepeye® TPS

deepeye® TPS nAMD (**therapy planning support**) is a medical device (CE 1912) for **predictive therapy decision support** clinicians treating nAMD patients. Information about the scope of application and the limitations of the algorithm can be found in the electronic instructions for use.

In addition, it fulfills the **requirements** of the **EU AI Act**, e.g. in terms of **transparency, human oversight** and **traceability**.

deepeye® TPS also fulfills the statements and **ethical guidelines for AI in ophthalmology** by **BVA, DOG** and **EURETINA**.



anti-VEGF AI Assistant (nAMD)




Disease activity
for interval planning





Stratification
Good ↔ Bad
Responder,
Prediction
12 months




B-Scan: 25 of 49





B-Scan with most IRF (25 of 49 B-Scans)




B-Scan: 27 of 49




B-Scan with most SRF (27 of 49 B-Scans)



B-Scan: 21 of 49



B-Scan with most PED (21 of 49 B-Scans)



Summary of the AI report (this is not a medical report, just merely a summary of the AI results).


- The OCT of the patient shows **high** disease activity in the **right eye** on **13.09.2024**
- Most intraretinal fluid was seen in B-Scan 25 of 49. Most subretinal fluid in B-Scan 27. Highest PED in B-Scan 21.
- The long-term prognosis shows a trend towards **high** disease activity.



Relevant
biomarkers
+ Trends

Summary for
case documentation

Device-agnostic & cross-platform



Double reading improves VA & persistence

